Home  |  Contact

UniProtKB/Swiss-Prot O95140: Variant p.Gln276Arg

Mitofusin-2
Gene: MFN2
Variant information

Variant position:  276
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Type of variant:  LP/P [Disclaimer]
The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance

Residue change:  From Glutamine (Q) to Arginine (R) at position 276 (Q276R, p.Gln276Arg).
Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.

Physico-chemical properties:  Change from medium size and polar (Q) to large size and basic (R)
The physico-chemical property of the reference and variant residues and the change implicated.

BLOSUM score:  1
The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page

Variant description:  In HMSN6A.
Any additional useful information about the variant.

Other resources:  
Links to websites of interest for the variant.



Sequence information

Variant position:  276
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Protein sequence length:  757
The length of the canonical sequence.

Location on the sequence:   LNNRWDASASEPEYMEEVRR  Q HMERCTSFLVDELGVVDRSQ
The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.

Residue conservation: 
The multiple alignment of the region surrounding the variant against various orthologous sequences.

Human                         LNNRWDASASEPEYMEEVRRQHMERCTSFLVDELGVVDRSQ

Mouse                         LNNRWDASASEPEYMEEVRRQHMERCTSFLVDELGVVDRAQ

Rat                           LNNRWDASASEPEYMEEVRRQHMERCTSFLVDELGVVDRAQ

Sequence annotation in neighborhood:  
The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.

TypePositionsDescription
Chain 1 – 757 Mitofusin-2
Topological domain 1 – 604 Cytoplasmic
Domain 93 – 342 Dynamin-type G
Region 288 – 288 G5 motif
Alternative sequence 1 – 302 Missing. In isoform 2.
Mutagenesis 259 – 259 R -> A. Loss of function in promoting mitochondrial fusion.
Mutagenesis 259 – 259 R -> L. Does not affect its ability to cluster mitochondria; when overexpressed.
Mutagenesis 260 – 260 W -> A. Loss of function in promoting mitochondrial fusion.
Mutagenesis 266 – 266 E -> A. Loss of function in promoting mitochondrial fusion.
Helix 270 – 287


Literature citations

Axonal neuropathy with optic atrophy is caused by mutations in mitofusin 2.
Zuechner S.; De Jonghe P.; Jordanova A.; Claeys K.G.; Guergueltcheva V.; Cherninkova S.; Hamilton S.R.; Van Stavern G.; Krajewski K.M.; Stajich J.; Tournev I.; Verhoeven K.; Langerhorst C.T.; de Visser M.; Baas F.; Bird T.; Timmerman V.; Shy M.; Vance J.M.;
Ann. Neurol. 59:276-281(2006)
Cited for: VARIANTS HMSN6A TRP-94; ILE-206; ARG-276; TYR-361 AND TRP-364;

Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.